RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Michael C. Campbell to Drug Screening Assays, Antitumor

Back to Details
This is a "connection" page, showing publications Michael C. Campbell has written about Drug Screening Assays, Antitumor.
Michael C. Campbell
Connection Strength
0.093
Drug Screening Assays, Antitumor
  1. Liu W, Mousa AAK, Hopkins AM, Wu YF, Thu KL, Campbell M, Lees SJ, Ramachandran R, Hou J. Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer. ChemMedChem. 2024 Aug 19; 19(16):e202400013.
    View in: PubMed
    Score: 0.052
  2. Weaver MJ, Stump S, Campbell MJ, Backos DS, Li C, Reigan P, Adams E, Beall HD, Natale NR. 10-N-heterocylic aryl-isoxazole-amides (AIMs) have robust anti-tumor activity against breast and brain cancer cell lines and useful fluorescence properties. Bioorg Med Chem. 2020 11 15; 28(22):115781.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support